You must register prior to attempting to obtain CE credit for the presentation. If you click on the presentation it doesn’t open up, go to upper left hand corner of your screen and click on the icon that looks like a screen with a start button.
*The presentation requires your computer to have Power Point 2013 or a more current version to run successfully.*
This presentation is being presented by:
Gillian M. Kuszewski, PharmD, BCPS
Pharmacy Clinical Coordinator – Inpatient Pharmacy Services
UConn Health Center, Farmington, CT
- Counseling Documentation Form
- Naloxone IN or IM Kit Patient Information
- Narcan nasal spray Patient Information
- Evzio Patient Information
- Overdose Flyer
- Project ASSERT Brochure
- DCP’s primary source of information that is focused on pharmacists
- General Naloxone Information
Jointly provided by Connecticut Pharmacists Association (CPA) and UConn School of Pharmacy in collaboration with the State of Connecticut Department of Consumer Protection – Drug Control Division; State of Connecticut Department of Mental Health and Addiction Services; Connecticut State Medical Society; and the University of Saint Joseph School of Pharmacy
In this knowledge-based continuing pharmacy education activity Dr. Gillian Kuszewski, PharmD will discuss the use of naloxone in the prevention of death from opiate overdose and the CT regulations for pharmacist prescribing and dispensing of naloxone.
Pharmacists who are interested in the prevention of death from opiate overdose and those who wish to participate in the CT program for naloxone prescribing and dispensing.
This activity is not accredited for technicians
At the conclusion of the activity, pharmacists will be able to:
- Identify the risk factors for and clinical presentation of a person with an opioid overdose
- Discuss naloxone use as an opioid antagonist
- Describe naloxone prescribing and dispensing instructions for intranasal and intramuscular dosage forms
- Discuss how to administer intranasal and intramuscular naloxone
- Review current CT state laws regarding naloxone access
- Describe proper counseling points and technique
- Discuss the referral of patients and caregivers to support programs, 211, and physicians specializing in addiction services
Activity Faculty:Gillian M. Kuszewski, Pharm.D
UConn Health Center
Presentation was prepared by: State of Connecticut Department of Consumer Protection – Drug Control Division; Connecticut Pharmacists Association; State of Connecticut Department of Mental Health and Addiction Services; Connecticut State Medical Society; and the University of Saint Joseph and University of Connecticut – Schools of Pharmacy.
In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.
Gillian M. Kuszewski, Pharm.D, has no actual or potential conflicts of interest associated with this presentation.
The following contributors have no actual or potential conflicts of interest associated with this presentation.
Representatives from the State of Connecticut Department of Consumer Protection – Drug Control Division; Connecticut Pharmacists Association; State of Connecticut Department of Mental Health and Addiction Services; Connecticut State Medical Society; and the University of Saint Joseph and University of Connecticut – Schools of Pharmacy.
Click on the registration link to register for this activity. The cost is $50.00. Register
There is no funding for this activity.
The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 2 contact hour (0.2 CEU) will be awarded to pharmacists who view the presentation, pass the quiz with a grade of 70% or better, and complete an evaluation. (ACPE #0009-9999-18-077-H03-P) Statements of credit will be electronically transmitted to CPE Monitor within 72 hours of completing the activity.
Initial release date: August 29, 2018
Planned expiration date: August 29, 2021
The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy, Connecticut Pharmacist Association or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be